Viking Therapeutics, Inc.
VKTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Viking Therapeutics, Inc. focuses on Biotechnology services and products. Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. At a $3.10B market cap, Viking Therapeutics, Inc. ranks as a mid-cap company within healthcare. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Market Cap
$3.10B
Beta
0.65
P/E (TTM)
—
P/E (Fwd)
-5.62
EPS (TTM)
$-4.67
EPS (Fwd)
$-4.34
ROE
-88.8%
ROA
-51.9%
Cash
$501.7M
Total Debt
$4.1M
Free CF
-$230.8M
52W Change
-32.1%
Annual Financials
Cash vs Debt
Where VKTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, VKTX finished 23.98% below its 150-day moving average ($32.95) and 23.42% below its 200-day moving average ($32.71). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VKTX overbought or oversold?
At the October 20, 2026 close, VKTX's RSI(14) was 25.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Viking Therapeutics, Inc. holds $501.7M in cash against $4.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$230.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -88.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Viking Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Viking Therapeutics, Inc.'s trajectory.